Neuland Laboratories Limited (NEULANDLAB.BO)
INR 11705.4
(6.96%)
INR 11705.4
(6.96%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3 Billion INR | 83.51% |
| 2022 | 1.63 Billion INR | 156.21% |
| 2021 | 638.22 Million INR | -20.85% |
| 2020 | 806.3 Million INR | 397.4% |
| 2019 | 162.1 Million INR | -1.41% |
| 2018 | 164.41 Million INR | 36.3% |
| 2017 | 120.62 Million INR | -74.26% |
| 2016 | 468.64 Million INR | 71.51% |
| 2015 | 273.24 Million INR | 71.35% |
| 2014 | 159.46 Million INR | -40.51% |
| 2013 | 268.07 Million INR | 93.35% |
| 2012 | 138.64 Million INR | 441.39% |
| 2011 | 25.61 Million INR | -51.58% |
| 2010 | 52.89 Million INR | 176.6% |
| 2009 | -69.05 Million INR | -157.91% |
| 2008 | 119.23 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 978.72 Million INR | 44.86% |
| 2023 Q2 | 892.47 Million INR | 44.23% |
| 2023 Q1 | 618.79 Million INR | -26.81% |
| 2023 FY | 3 Billion INR | 83.51% |
| 2023 Q4 | 675.61 Million INR | -16.99% |
| 2023 Q3 | 813.9 Million INR | -8.8% |
| 2022 Q3 | 305.48 Million INR | -20.57% |
| 2022 Q2 | 384.59 Million INR | 285.92% |
| 2022 FY | 1.63 Billion INR | 156.21% |
| 2022 Q1 | 99.65 Million INR | -54.24% |
| 2022 Q4 | 845.43 Million INR | 176.76% |
| 2021 FY | 638.22 Million INR | -20.85% |
| 2021 Q4 | 217.8 Million INR | 68.38% |
| 2021 Q3 | 129.35 Million INR | -36.5% |
| 2021 Q2 | 203.71 Million INR | 133.23% |
| 2021 Q1 | 87.34 Million INR | -49.49% |
| 2020 Q1 | 151.63 Million INR | 263.12% |
| 2020 Q3 | 267.35 Million INR | 24.7% |
| 2020 Q4 | 172.92 Million INR | -35.32% |
| 2020 Q2 | 214.4 Million INR | 41.4% |
| 2020 FY | 806.3 Million INR | 397.4% |
| 2019 Q3 | 111.1 Million INR | 27.87% |
| 2019 FY | 162.1 Million INR | -1.41% |
| 2019 Q2 | 86.88 Million INR | 52.24% |
| 2019 Q4 | -92.95 Million INR | -183.67% |
| 2019 Q1 | 57.07 Million INR | -13.93% |
| 2018 FY | 164.41 Million INR | 36.3% |
| 2018 Q1 | 5.68 Million INR | 0.0% |
| 2018 Q2 | 45.51 Million INR | 701.09% |
| 2018 Q3 | 46.91 Million INR | 3.09% |
| 2018 Q4 | 66.3 Million INR | 41.33% |
| 2017 FY | 120.62 Million INR | -74.26% |
| 2016 Q3 | 63.51 Million INR | -38.86% |
| 2016 FY | 468.64 Million INR | 71.51% |
| 2016 Q2 | 103.88 Million INR | 3.37% |
| 2016 Q4 | 204.13 Million INR | 221.39% |
| 2016 Q1 | 100.5 Million INR | 0.0% |
| 2015 FY | 273.24 Million INR | 71.35% |
| 2014 FY | 159.46 Million INR | -40.51% |
| 2013 FY | 268.07 Million INR | 93.35% |
| 2012 FY | 138.64 Million INR | 441.39% |
| 2011 FY | 25.61 Million INR | -51.58% |
| 2010 FY | 52.89 Million INR | 176.6% |
| 2009 FY | -69.05 Million INR | -157.91% |
| 2008 FY | 119.23 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 96.866% |
| NATCO Pharma Limited | 13.88 Billion INR | 78.385% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 0.067% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -1085.417% |
| Achyut Healthcare Limited | 5.73 Million INR | -52251.518% |
| Ajanta Pharma Limited | 8.16 Billion INR | 63.233% |
| Alkem Laboratories Limited | 17.95 Billion INR | 83.29% |
| Alpa Laboratories Limited | 167.76 Million INR | -1688.686% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 51.272% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -85.796% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 90.543% |
| Bajaj HealthCare Limited | -837.93 Million INR | 458.119% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -297.697% |
| Brooks Laboratories Limited | -195.91 Million INR | 1631.648% |
| Divi's Laboratories Limited | 16 Billion INR | 81.245% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 94.611% |
| Eris Lifesciences Limited | 3.91 Billion INR | 23.446% |
| FDC Limited | 3.05 Billion INR | 1.685% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 119.983% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 36.274% |
| Granules India Limited | 4.05 Billion INR | 25.963% |
| Gufic Biosciences Limited | 861.35 Million INR | -248.38% |
| Hester Biosciences Limited | 188.89 Million INR | -1488.644% |
| Indoco Remedies Limited | 984.6 Million INR | -204.772% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 28.716% |
| Ipca Laboratories Limited | 5.47 Billion INR | 45.176% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -1235.881% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 1621.05% |
| Lasa Supergenerics Limited | -217.3 Million INR | 1480.905% |
| Laurus Labs Limited | 1.6 Billion INR | -86.907% |
| Lupin Limited | 19.14 Billion INR | 84.326% |
| Mankind Pharma Limited | 19.12 Billion INR | 84.313% |
| Medicamen Biotech Limited | 109.31 Million INR | -2645.21% |
| Medico Remedies Limited | 82.9 Million INR | -3519.377% |
| Megasoft Limited | -127.46 Million INR | 2454.188% |
| Piramal Pharma Limited | 178.2 Million INR | -1583.944% |
| RPG Life Sciences Limited | 876.6 Million INR | -242.321% |
| Sigachi Industries Limited | 571.8 Million INR | -424.795% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 177.497% |
| Unichem Laboratories Limited | -704.74 Million INR | 525.799% |
| Wanbury Limited | 559.56 Million INR | -436.274% |
| Windlas Biotech Limited | 581.87 Million INR | -415.715% |
| ZIM Laboratories Limited | 172.46 Million INR | -1639.951% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 92.225% |
| Procter & Gamble Health Limited | 2 Billion INR | -49.308% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -567.248% |
| Bal Pharma Limited | 73.92 Million INR | -3959.399% |
| Strides Pharma Science Limited | -706.14 Million INR | 524.957% |
| Venus Remedies Limited | 284.9 Million INR | -953.248% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -38.348% |
| Nectar Lifesciences Limited | 49.95 Million INR | -5907.586% |
| Shilpa Medicare Limited | 318.74 Million INR | -841.448% |
| Aarti Drugs Limited | 1.71 Billion INR | -75.057% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -123.223% |
| Suven Life Sciences Limited | -1.05 Billion INR | 385.582% |
| Ind-Swift Limited | 142.31 Million INR | -2008.584% |
| Valiant Laboratories Limited | 3.19 Million INR | -93792.021% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 45.7% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 152.888% |
| Themis Medicare Limited | 435.23 Million INR | -589.459% |
| Hikal Limited | 696.02 Million INR | -331.135% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 81.883% |
| Sequent Scientific Limited | -358.69 Million INR | 936.597% |
| Novartis India Limited | 851.9 Million INR | -252.247% |
| Wockhardt Limited | -4.63 Billion INR | 164.812% |
| Jubilant Pharmova Limited | 771 Million INR | -289.207% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -42212.31% |
| Morepen Laboratories Limited | 961.59 Million INR | -212.062% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -1955.138% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 3407.857% |